人福医药：子公司注射用苯磺酸瑞马唑仑获得药品注册证书

Group 1 - The core point of the article is that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the injection of remimazolam benzenesulfonate, expanding its usage in sedation during mechanical ventilation in intensive care [1] - The newly approved indication for remimazolam benzenesulfonate is as a sedative for patients undergoing mechanical ventilation in intensive care, which is expected to broaden the product's application [1] - The future sales performance of this product may be influenced by industry policies and market conditions, indicating a level of uncertainty [1]